Status:
COMPLETED
A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects
Lead Sponsor:
Zhejiang Wenda Pharma Technology LTD.
Conditions:
Healthy Participants
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-890 Tablets in Healthy Chin...
Eligibility Criteria
Inclusion
- Inclusion Criteria：
- Signed Informed Consent.
- 18 Years to 50 Years (Adult).
- Body mass index (BMI) of 19 to 26 kg/m2, inclusive, and total body weight ：male \>=50 kg; female \>= 45.0 kg.
- Exclusion Criteria：
- Has any surgery performed within 6 months prior to screening, or during the study period.
- Inability to swallow solid tablets.
- Inability to be venipunctured and tolerate venous access.
Exclusion
Key Trial Info
Start Date :
October 26 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2024
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT06506591
Start Date
October 26 2023
End Date
August 15 2024
Last Update
March 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430056